Wells Fargo & Company Catalyst Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

$433 Billion
Q4 2024

A detailed history of Wells Fargo & Company transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 82,820 shares of CPRX stock, worth $1.89 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

82,820

Previous 155,931 46.89%

Holding current value

$1.89 Million

Previous $3.1 Million 44.24%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	SELL	$19.73 - $23.93 $1.44 Million - $1.75 Million	-73,111 Reduced 46.89%	82,820 $1.73 Million
Q3 2024 Nov 13, 2024	BUY	$15.19 - $21.35 $1.77 Million - $2.49 Million	116,747 Added 297.95%	155,931 $3.1 Million
Q2 2024 Aug 13, 2024	BUY	$14.68 - $16.92 $25,895 - $29,846	1,764 Added 4.71%	39,184 $606,000
Q1 2024 May 10, 2024	BUY	$13.18 - $17.11 $119,634 - $155,307	9,077 Added 32.03%	37,420 $596,000
Q4 2023 Feb 09, 2024	SELL	$11.78 - $17.29 $1.12 Million - $1.64 Million	-94,680 Reduced 76.96%	28,343 $476,000
Q3 2023 Nov 13, 2023	SELL	$11.69 - $15.02 $618,588 - $794,798	-52,916 Reduced 30.08%	123,023 $1.44 Million
Q2 2023 Aug 15, 2023	BUY	$11.5 - $18.08 $469,027 - $737,392	40,785 Added 30.18%	175,939 $2.36 Million
Q1 2023 May 12, 2023	BUY	$14.34 - $21.05 $990,148 - $1.45 Million	69,048 Added 104.45%	135,154 $2.24 Million
Q4 2022 Feb 13, 2023	BUY	$12.25 - $19.5 $199,319 - $317,284	16,271 Added 32.65%	66,106 $1.23 Million
Q3 2022 Nov 14, 2022	BUY	$7.06 - $15.52 $257,061 - $565,098	36,411 Added 271.24%	49,835 $640,000
Q2 2022 Aug 12, 2022	SELL	$6.23 - $8.57 $2.12 Million - $2.92 Million	-340,600 Reduced 96.21%	13,424 $94,000
Q1 2022 May 16, 2022	SELL	$5.31 - $8.31 $313,629 - $490,821	-59,064 Reduced 14.3%	354,024 $2.94 Million
Q4 2021 Feb 14, 2022	SELL	$5.21 - $7.45 $1.81 Million - $2.58 Million	-346,570 Reduced 45.62%	413,088 $2.8 Million
Q3 2021 Nov 15, 2021	SELL	$4.85 - $6.04 $103,950 - $129,455	-21,433 Reduced 2.74%	759,658 $4.03 Million
Q2 2021 Aug 16, 2021	BUY	$4.29 - $6.05 $2.83 Million - $3.99 Million	659,072 Added 540.14%	781,091 $4.49 Million
Q1 2021 May 13, 2021	SELL	$3.45 - $4.69 $394,648 - $536,493	-114,391 Reduced 48.39%	122,019 $562,000
Q4 2020 Feb 09, 2021	SELL	$2.97 - $3.83 $199,797 - $257,651	-67,272 Reduced 22.15%	236,410 $790,000
Q3 2020 Nov 05, 2020	BUY	$2.97 - $5.08 $127,208 - $217,581	42,831 Added 16.42%	303,682 $902,000
Q2 2020 Aug 13, 2020	BUY	$3.48 - $5.05 $122,092 - $177,174	35,084 Added 15.54%	260,851 $1.21 Million
Q1 2020 May 14, 2020	BUY	$2.61 - $5.21 $589,251 - $1.18 Million	225,767 New	225,767 $869,000

Others Institutions Holding CPRX

# of Institutions

351

Shares Held

98.5M

Call Options Held

13.4K

Put Options Held

11.7K

View Full List

About CATALYST PHARMACEUTICALS, INC.

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.34B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

More about CPRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Catalyst Pharmaceuticals, Inc. Transaction History